2011
DOI: 10.1186/1897-4287-9-s2-a4
|View full text |Cite
|
Sign up to set email alerts
|

Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
10
0
1

Year Published

2013
2013
2022
2022

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 12 publications
(11 citation statements)
references
References 0 publications
0
10
0
1
Order By: Relevance
“…Baseado nisso, silver conduziu estudo com cisplatina pré-operatória e observou prc em 22% 19 . um pequeno estudo incluindo apenas pacientes portadoras de mutação de Brca1 e usando cisplatina exclusiva mostrou a surpreendente taxa de prc de 72% 20 . novos estudos devem ser conduzidos testando a incorporação de derivados de platina na neoadjuvância, ainda que em subgrupos selecionados.…”
Section: Resultsunclassified
“…Baseado nisso, silver conduziu estudo com cisplatina pré-operatória e observou prc em 22% 19 . um pequeno estudo incluindo apenas pacientes portadoras de mutação de Brca1 e usando cisplatina exclusiva mostrou a surpreendente taxa de prc de 72% 20 . novos estudos devem ser conduzidos testando a incorporação de derivados de platina na neoadjuvância, ainda que em subgrupos selecionados.…”
Section: Resultsunclassified
“…It makes sense that BRCA1-deficient tumor cells are five times more sensitive to the DNA-damaging agent cisplatin compared with normal cells (Bhattacharyya, Ear, Koller, Weichselbaum, & Bishop, 2000). Gronwald et al's (2009) study supported the biologic rationale for these therapies because 72% of BRCA1-deficient women were observed to have complete pathologic response when treated with a cisplatin regimen.…”
Section: Current Clinical Targetsmentioning
confidence: 90%
“…Platinum salts such as carboplatin and cisplatin exert their cytotoxic effects through distinct cellular mechanisms [ 76 ]; more specifically, after entrance into cells, platinum salts react with DNA generating monoadducts, inter- and intraDNA strand cross-links, and are able to cause SSBs and DSBs [ 77 ]. Consequently, DNA replication and transcription are blocked by this structural distortion, resulting in cell cycle arrest, cell apoptosis, and necrosis [ 78 ]. In physiological conditions, DNA lesions caused by platinum salts are properly repaired by DDR mechanisms; therefore, since platinum salts are DNA cross-linking agents, it is readily apparent that these compounds are more likely to be effective in BRCAm malignancies [ 79 ].…”
Section: Parpi In Btcmentioning
confidence: 99%